Latent Membrane Protein 2A Inhibits Transforming Growth Factor-beta 1-induced Apoptosis Through the Phosphatidylinositol 3-kinase/Akt Pathway

Overview

Journal J Virol

Publisher American Society for Microbiology

Date 2004 Jan 30

PMID 14747535

Citations 61

Authors

Makoto Fukuda

Richard Longnecker

Affiliations

Soon will be listed here.

Abstract

Latent membrane protein 2A (LMP2A) blocks B-cell receptor signal transduction in vitro by binding the Syk and Lyn protein tyrosine kinases. As well as blocking B-cell signal transduction, LMP2A has been shown to activate the phosphatidylinositol 3-kinase (PI3-K)/Akt pathway, which acts as a survival signal in both B cells and epithelial cells. Transforming growth factor beta 1 (TGF-beta 1) is a multifunctional cytokine that plays important roles in regulating cell growth and differentiation in many biological systems. The loss of the growth-inhibitory response to the TGF-beta 1 signal is found in many cancers and is widely thought to promote tumor development. In this study, we found that LMP2A induced the phosphorylation of Akt (serine 473) in Burkitt's lymphoma cell line Ramos and in gastric carcinoma cell line HSC-39 and partially enhanced cell viability following TGF-beta 1 treatment. In addition, LMP2A partially inhibited TGF-beta 1-induced DNA fragmentation and cleavage of poly(ADP-ribose) polymerase (PARP). In the presence of LY294002, an inhibitor of PI3-K, the LMP2A-mediated inhibitory effects on TGF-beta 1-induced DNA fragmentation and cleavage of PARP were alleviated. Furthermore, LMP2A did not alter the levels of expression of type I and type II TGF-beta 1 receptors. Taken together, these results suggest that LMP2A may inhibit TGF-beta 1-mediated apoptosis through activation of the PI3-K/Akt pathway.

Citing Articles

Epstein-Barr Virus Latent Membrane Protein 2A (LMP2A) Enhances ATP Production in B Cell Tumors through mTOR and HIF-1α.

Incrocci R, Monroy Del Toro R, Devitt G, Salimian M, Braich K, Swanson-Mungerson M Int J Mol Sci. 2024; 25(7).

PMID: 38612754 PMC: 11012313. DOI: 10.3390/ijms25073944.

Pathogenesis and therapeutic implications of EBV-associated epithelial cancers.

Low Y, Loh C, Peh D, Chu A, Han S, Toh H Front Oncol. 2023; 13:1202117.

PMID: 37901329 PMC: 10600384. DOI: 10.3389/fonc.2023.1202117.

Onco-Pathogen Mediated Cancer Progression and Associated Signaling Pathways in Cancer Development.

Kannampuzha S, Gopalakrishnan A, Padinharayil H, Alappat R, Anilkumar K, George A Pathogens. 2023; 12(6).

PMID: 37375460 PMC: 10305322. DOI: 10.3390/pathogens12060770.

Contribution of Epstein-Barr Virus Lytic Proteins to Cancer Hallmarks and Implications from Other Oncoviruses.

Dorothea M, Xie J, Yiu S, Chiang A Cancers (Basel). 2023; 15(7).

PMID: 37046781 PMC: 10093119. DOI: 10.3390/cancers15072120.

The impact of Epstein-Barr virus latent membrane protein 2A on the production of B cell activating factor of the tumor necrosis factor family (BAFF), APRIL and their receptors.

Madayag K, Incrocci R, Swanson-Mungerson M Immun Inflamm Dis. 2022; 10(11):e729.

PMID: 36301035 PMC: 9597489. DOI: 10.1002/iid3.729.

References

Saltzman A, Munro R, Searfoss G, Franks C, Jaye M, Ivashchenko Y . Transforming growth factor-beta-mediated apoptosis in the Ramos B-lymphoma cell line is accompanied by caspase activation and Bcl-XL downregulation. Exp Cell Res. 1998; 242(1):244-54. DOI: 10.1006/excr.1998.4096. View

Mizoi T, Ohtani H, Miyazono K, Miyazawa M, Matsuno S, Nagura H . Immunoelectron microscopic localization of transforming growth factor beta 1 and latent transforming growth factor beta 1 binding protein in human gastrointestinal carcinomas: qualitative difference between cancer cells and stromal cells. Cancer Res. 1993; 53(1):183-90. View

Inman G, Allday M . Resistance to TGF-beta1 correlates with a reduction of TGF-beta type II receptor expression in Burkitt's lymphoma and Epstein-Barr virus-transformed B lymphoblastoid cell lines. J Gen Virol. 2000; 81(Pt 6):1567-78. DOI: 10.1099/0022-1317-81-6-1567. View

Dahl J, Jurczak A, Cheng L, Baker D, BENJAMIN T . Evidence of a role for phosphatidylinositol 3-kinase activation in the blocking of apoptosis by polyomavirus middle T antigen. J Virol. 1998; 72(4):3221-6. PMC: 109788. DOI: 10.1128/JVI.72.4.3221-3226.1998. View

Yao R, Cooper G . Requirement for phosphatidylinositol-3 kinase in the prevention of apoptosis by nerve growth factor. Science. 1995; 267(5206):2003-6. DOI: 10.1126/science.7701324. View

Chen S, Lu J, Tsai C . Epstein-Barr virus latent membrane protein 2A regulates c-Jun protein through extracellular signal-regulated kinase. J Virol. 2002; 76(18):9556-61. PMC: 136421. DOI: 10.1128/jvi.76.18.9556-9561.2002. View

Ahmed N, Grimes H, Bellacosa A, Chan T, Tsichlis P . Transduction of interleukin-2 antiapoptotic and proliferative signals via Akt protein kinase. Proc Natl Acad Sci U S A. 1997; 94(8):3627-32. PMC: 20491. DOI: 10.1073/pnas.94.8.3627. View

Ohta S, Yanagihara K, Nagata K . Mechanism of apoptotic cell death of human gastric carcinoma cells mediated by transforming growth factor beta. Biochem J. 1997; 324 ( Pt 3):777-82. PMC: 1218492. DOI: 10.1042/bj3240777. View

del Peso L, Gonzalez-Garcia M, Page C, Herrera R, Nunez G . Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science. 1997; 278(5338):687-9. DOI: 10.1126/science.278.5338.687. View

10.

Zha J, Harada H, Yang E, Jockel J, Korsmeyer S . Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X(L). Cell. 1996; 87(4):619-28. DOI: 10.1016/s0092-8674(00)81382-3. View

11.

Moody C, Scott R, Su T, Sixbey J . Length of Epstein-Barr virus termini as a determinant of epithelial cell clonal emergence. J Virol. 2003; 77(15):8555-61. PMC: 165260. DOI: 10.1128/jvi.77.15.8555-8561.2003. View

12.

Xu J, Ahmad A, Jones J, Dolcetti R, Vaccher E, Prasad U . Elevated serum transforming growth factor beta1 levels in Epstein-Barr virus-associated diseases and their correlation with virus-specific immunoglobulin A (IgA) and IgM. J Virol. 2000; 74(5):2443-6. PMC: 111728. DOI: 10.1128/jvi.74.5.2443-2446.2000. View

13.

Miller C, Burkhardt A, Lee J, Stealey B, Longnecker R, Bolen J . Integral membrane protein 2 of Epstein-Barr virus regulates reactivation from latency through dominant negative effects on protein-tyrosine kinases. Immunity. 1995; 2(2):155-66. DOI: 10.1016/s1074-7613(95)80040-9. View

14.

Tahara E . Molecular mechanism of stomach carcinogenesis. J Cancer Res Clin Oncol. 1993; 119(5):265-72. DOI: 10.1007/BF01212724. View

15.

Naef M, Ishiwata T, Friess H, Buchler M, Gold L, Korc M . Differential localization of transforming growth factor-beta isoforms in human gastric mucosa and overexpression in gastric carcinoma. Int J Cancer. 1997; 71(2):131-7. DOI: 10.1002/(sici)1097-0215(19970410)71:2<131::aid-ijc1>3.0.co;2-1. View

16.

Kim S, Kim S, Jong H, Kim N, Hong S, Kim S . Caspase-mediated Cdk2 activation is a critical step to execute transforming growth factor-beta1-induced apoptosis in human gastric cancer cells. Oncogene. 2001; 20(10):1254-65. DOI: 10.1038/sj.onc.1204203. View

17.

Inman G, Allday M . Apoptosis induced by TGF-beta 1 in Burkitt's lymphoma cells is caspase 8 dependent but is death receptor independent. J Immunol. 2000; 165(5):2500-10. DOI: 10.4049/jimmunol.165.5.2500. View

18.

Letterio J, Roberts A . Regulation of immune responses by TGF-beta. Annu Rev Immunol. 1998; 16:137-61. DOI: 10.1146/annurev.immunol.16.1.137. View

19.

Klein G, GIOVANELLA B, Westman A, STEHLIN J, Mumford D . An EBV-genome-negative cell line established from an American Burkitt lymphoma; receptor characteristics. EBV infectibility and permanent conversion into EBV-positive sublines by in vitro infection. Intervirology. 1975; 5(6):319-34. DOI: 10.1159/000149930. View

20.

Mok C, Gil-Gomez G, Williams O, Coles M, Taga S, Tolaini M . Bad can act as a key regulator of T cell apoptosis and T cell development. J Exp Med. 1999; 189(3):575-86. PMC: 2192908. DOI: 10.1084/jem.189.3.575. View